A J M Ferreri
Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
Jörger M, Huitema A, Illerhaus G, Ferreri A. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 2012; 53:1867-75.
May 21, 2012Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
May 21, 2012Leuk Lymphoma 2012; 53:1867-75
Jörger Markus, Huitema A D R, Illerhaus G, Ferreri A J M
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Jörger M, Huitema A, Illerhaus G, Ferreri A. High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?. Leuk Lymphoma 2011; 52:1825-7.
Jun 10, 2011High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Jun 10, 2011Leuk Lymphoma 2011; 52:1825-7
Jörger Markus, Huitema A D R, Illerhaus G, Ferreri A J M
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
Feb 2, 2010Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Feb 2, 2010Br J Cancer 2010; 102:673-7
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M